These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 32213105)

  • 1. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
    Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
    Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
    Kindler HL; Novello S; Bearz A; Ceresoli GL; Aerts JGJV; Spicer J; Taylor P; Nackaerts K; Greystoke A; Jennens R; Calabrò L; Burgers JA; Santoro A; Cedrés S; Serwatowski P; Ponce S; Van Meerbeeck JP; Nowak AK; Blumenschein G; Siegel JM; Kasten L; Köchert K; Walter AO; Childs BH; Elbi C; Hassan R; Fennell DA
    Lancet Oncol; 2022 Apr; 23(4):540-552. PubMed ID: 35358455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
    Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
    Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
    Lazzerini L; Jöhrens K; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2020 Nov; 302(5):1255-1262. PubMed ID: 32815024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F; Haeder T; Wartenberg-Demand A; Anderson KC
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):372-380. PubMed ID: 30930134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
    Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study.
    Ma Y; Huang Y; Zhao Y; Zhao S; Xue J; Yang Y; Fang W; Guo Y; Han Y; Yang K; Li Y; Yang J; Fu Z; Chen G; Chen L; Zhou N; Zhou T; Zhang Y; Zhou H; Liu Q; Zhu Y; Zhu H; Xiao S; Zhang L; Zhao H
    Lancet Oncol; 2024 Jul; 25(7):901-911. PubMed ID: 38823410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
    de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
    Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
    Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
    Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
    Banerji U; van Herpen CML; Saura C; Thistlethwaite F; Lord S; Moreno V; Macpherson IR; Boni V; Rolfo C; de Vries EGE; Rottey S; Geenen J; Eskens F; Gil-Martin M; Mommers EC; Koper NP; Aftimos P
    Lancet Oncol; 2019 Aug; 20(8):1124-1135. PubMed ID: 31257177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelin as a target for cervical cancer therapy.
    Jöhrens K; Lazzerini L; Barinoff J; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2019 Jan; 299(1):211-216. PubMed ID: 30324544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
    Quanz M; Hagemann UB; Zitzmann-Kolbe S; Stelte-Ludwig B; Golfier S; Elbi C; Mumberg D; Ziegelbauer K; Schatz CA
    Oncotarget; 2018 Sep; 9(75):34103-34121. PubMed ID: 30344925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Kantarjian HM; Lioure B; Kim SK; Atallah E; Leguay T; Kelly K; Marolleau JP; Escoffre-Barbe M; Thomas XG; Cortes J; Jabbour E; O'Brien S; Bories P; Oprea C; Hatteville L; Dombret H
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):139-45. PubMed ID: 26775883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
    Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
    J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
    Kollmannsberger C; Britten CD; Olszanski AJ; Walker JA; Zang W; Willard MD; Radtke DB; Farrington DL; Bell-McGuinn KM; Patnaik A
    Invest New Drugs; 2021 Dec; 39(6):1613-1623. PubMed ID: 34264412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
    Tabernero J; Bedard PL; Bang YJ; Vieito M; Ryu MH; Fagniez N; Chadjaa M; Soufflet C; Masson N; Gazzah A
    Cancer Res Commun; 2023 Aug; 3(8):1662-1671. PubMed ID: 37645622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.